InvestorsHub Logo
Followers 2
Posts 385
Boards Moderated 0
Alias Born 09/20/2017

Re: Spideyboy post# 2528

Tuesday, 10/09/2018 8:19:44 PM

Tuesday, October 09, 2018 8:19:44 PM

Post# of 3999
Hi Spideyboy!
Thanks for the detailed answer, I think that the Protalix' promises regarding PRX-102( first in class, gold standard therapy, $1B in sales) will soon become a reality. I recently read Clinical Review Report for Galafold.How do you like the following statement

Changes in renal function were evaluated as secondary end points in the FACETS trial.
The six-month change in mean (± SEM) mGFR in the ITT analysis in FACETS was -1.19 ±3.4 mL/min/1.73 m2 in the migalastat group (n = 34)
and 0.41 ± 2.0 mL/min/1.73 m2 in the placebo group (n = 33).7
These results indicate that patients may have had better
stabilization of GFR in the placebo group than the migalastat group.

I think that C.C.is a paid troll perhaps with the SA help as this is her fifth negative article on Protalix.
Have a look please at the GERN catastrophe after J&J broke off the contract with them.And after that they have M/C 3 times bigger than Protalix.Someone makes good money on PLX shortening and they can pay even such a slacker as C.C.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News